Lily Llorens

1.4k total citations
22 papers, 756 citations indexed

About

Lily Llorens is a scholar working on Epidemiology, Infectious Diseases and Pharmacology. According to data from OpenAlex, Lily Llorens has authored 22 papers receiving a total of 756 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Epidemiology, 9 papers in Infectious Diseases and 6 papers in Pharmacology. Recurrent topics in Lily Llorens's work include Pneumonia and Respiratory Infections (9 papers), Antimicrobial Resistance in Staphylococcus (7 papers) and Antibiotics Pharmacokinetics and Efficacy (6 papers). Lily Llorens is often cited by papers focused on Pneumonia and Respiratory Infections (9 papers), Antimicrobial Resistance in Staphylococcus (7 papers) and Antibiotics Pharmacokinetics and Efficacy (6 papers). Lily Llorens collaborates with scholars based in United States, United Kingdom and India. Lily Llorens's co-authors include H. David Friedland, J. Armstrong, Helen Broadhurst, Paul Newell, John E. Mazuski, Leanne B. Gasink, Greg Stone, Jan Pachl, Paul B. Eckburg and Dirk Thye and has published in prestigious journals such as PLoS ONE, Neurology and Clinical Infectious Diseases.

In The Last Decade

Lily Llorens

21 papers receiving 737 citations

Peers

Countries citing papers authored by Lily Llorens

Since Specialization

Citations

This map shows the geographic impact of Lily Llorens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lily Llorens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lily Llorens more than expected).

Fields of papers citing papers by Lily Llorens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lily Llorens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lily Llorens. The network helps show where Lily Llorens may publish in the future.

Co-authorship network of co-authors of Lily Llorens

This figure shows the co-authorship network connecting the top 25 collaborators of Lily Llorens. A scholar is included among the top collaborators of Lily Llorens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lily Llorens. Lily Llorens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of a 3-day once-daily regimen of oral nafithromycin in comparison to oral moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults: a phase III, randomized, double-blind controlled trial 2025 ·The Lancet Regional Health - Southeast Asia ·(unknown), Monica Gupta, Lily Llorens, Piotr Iwanowski, (unknown), (unknown), (unknown), Harsh Agrawal, (unknown), Prashant Joshi, Hariharan Periasamy, Mahesh Patel, Balaji Veeraraghavan, Sachin Bhagwat	0
2	Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia 2022 ·Frontiers in Neurology ·Rajesh Pahwa, Susan H. Fox, Robert A. Hauser, Stuart Isaacson, (unknown), Reed Johnson, Lily Llorens, (unknown), Caroline M. Tanner	6
3	A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment 2021 ·Multiple Sclerosis Journal ·Jeffrey A. Cohen, Michelle Cameron, Myla Goldman, Andrew Goodman, Aaron Miller, (unknown), Lily Llorens, Rajiv Patni, Robert Elfont, Reed Johnson	3
4	Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Openlabel, Randomized Study. 2020 ·PubMed ·Ashmeet Bhatia, (unknown), (unknown), (unknown), Prashant Joshi, (unknown), Hariharan Periasamy, (unknown), (unknown), Sachin Bhagwat, Mahesh Patel, Lily Llorens, H. David Friedland	21
5	Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial 2018 ·Multiple Sclerosis Journal ·Jeffrey A. Cohen, Samuel F. Hunter, Theodore R. Brown, Mark Gudesblatt, Ben Thrower, Lily Llorens, (unknown), (unknown), David Chernoff, Rajiv Patni	8
6	A Clinically Important Difference (CID) for the Unified Dyskinesia Rating Scale (UDysRS) Total Score Change in Parkinson’s Disease (PD) Patients with Dyskinesia (P2.052) 2018 ·Neurology ·Rajesh Pahwa, Caroline M. Tanner, Robert A. Hauser, Stuart Isaacson, Reed Johnson, (unknown), Rajiv Patni, Lily Llorens	2
7	Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point 2017 ·International Journal of Antimicrobial Agents ·Thomas M. File, Paul B. Eckburg, George H. Talbot, Lily Llorens, H. David Friedland	7
8	Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program 2016 ·Clinical Infectious Diseases ·John E. Mazuski, Leanne B. Gasink, J. Armstrong, Helen Broadhurst, Greg Stone, (unknown), Lily Llorens, Paul Newell, Jan Pachl	287
9	Patient-Reported Outcome Assessments as Endpoints in Studies in Infectious Diseases 2016 ·Clinical Infectious Diseases ·John H. Powers, Kellee Howard, (unknown), Sarah Clifford, (unknown), Lily Llorens, George H. Talbot	29
10	Development of a Patient-Reported outcome Instrument (Skinfect-Pro) To Standardize And Qualify Symptoms of Acute Bacterial Skin And Skin Structure Infection (Absssi) FNIH Biomarkers Consortium CABP ABSSSI Project Team ‘3 2015 ·Value in Health ·John H. Powers, Kellee Howard, (unknown), Sarah Clifford, (unknown), George H. Talbot, (unknown), Lily Llorens	2
11	Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials 2015 ·Journal of Antimicrobial Chemotherapy ·Maria Taboada, David Melnick, Joseph P. Iaconis, Fang Sun, Nan Zhong, Thomas M. File, Lily Llorens, H. David Friedland, David J. Wilson	21
12	Efficacy of Ceftaroline Fosamil for Bacteremia Associated With Community-Acquired Bacterial Pneumonia 2014 ·Hospital Practice ·Alena Jandourek, (unknown), Lily Llorens, Dirk Thye, Paul B. Eckburg, H. David Friedland	9
13	Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials 2013 ·Diagnostic Microbiology and Infectious Disease ·Andrew F. Shorr, Marin H. Kollef, Paul B. Eckburg, Lily Llorens, H. David Friedland	13
14	Evaluation of the Effect of a Supratherapeutic Dose of Intravenous Ceftaroline Fosamil on the Corrected QT Interval 2013 ·Antimicrobial Agents and Chemotherapy ·Todd Riccobene, Ludmyla Rekeda, (unknown), Lily Llorens	13
15	Panton-Valentine Leukocidin Is Not the Primary Determinant of Outcome for Staphylococcus aureus Skin Infections: Evaluation from the CANVAS Studies 2012 ·PLoS ONE ·(unknown), Steven Y. C. Tong, Yurong Zhang, Supaporn Lamlertthon, Batu K. Sharma‐Kuinkel, Thomas H. Rude, Sun Hee Ahn, Felicia Ruffin, Lily Llorens, (unknown), Donald Biek, Ian A. Critchley, Vance G. Fowler	27
16	CANVAS 1 and 2: Analysis of Clinical Response at Day 3 in Two Phase 3 Trials of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in Treatment of Acute Bacterial Skin and Skin Structure Infections 2012 ·Antimicrobial Agents and Chemotherapy ·H. David Friedland, Tanya O’Neal, Donald Biek, Paul B. Eckburg, (unknown), Lily Llorens, Alex Smith, Gary W. Witherell, (unknown), Dirk Thye	57
17	Day 4 Clinical Response of Ceftaroline Fosamil Versus Ceftriaxone for Community-Acquired Bacterial Pneumonia 2012 ·Infectious Diseases in Clinical Practice ·Paul B. Eckburg, H. David Friedland, Lily Llorens, (unknown), Gary W. Witherell, (unknown), Dirk Thye	19
18	Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled‐Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxone in Patients with Community‐Acquired Pneumonia 2010 ·Clinical Infectious Diseases ·Thomas M. File, Donald E. Low, Paul B. Eckburg, George H. Talbot, H. David Friedland, Jon Lee, Lily Llorens, Ian A. Critchley, Dirk Thye	146
19	FOCUS 1: Randomized, Double-blinded, Multicenter Phase 3 Study Of The Efficacy And Safety Of Ceftaroline Vs Ceftriaxone In Community-acquired Bacterial Pneumonia 2010 ·Paul B. Eckburg, David Friedland, Jon Lee, Lily Llorens, Ian A. Critchley, Dirk Thye	3
20	P833 Intravenous therapy with doripenem versus levofioxacin with an option for oral step-down therapy in the treatment of complicated urinary tract infections and pyelonephritis 2007 ·International Journal of Antimicrobial Agents ·Kurt G. Naber, Rebecca Redman, Paul Kotey, Lily Llorens, Koné Kaniga	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact